The Matrix and Metastasis Lab is based at the Garvan Institute of Medical Research Kinghorn Cancer Centre in Sydney, Australia.
Our research focuses on how the extracellular matrix (ECM) and ECM remodelling influences cancer progression, therapy response, and metastasis in solid tumours
Broad Research Areas:
Cancer, Cancer Cell Biology, Biochemistry, Proteomics
Society Memberships & Professional Activities:
Metastasis Research Society (MRS), Matrix Biology Society of Australia & New Zealand (MBSANZ)[Vice-President], British Society for Matrix Biology (BSMB), American Association for Cancer Research (AACR), British Association for Cancer Research (BACR)
Specific Research Keywords:
Extracellular Matrix, Cancer Metastasis, Targetted Therapies,
Our research focuses on how the ECM and ECM remodelling influences cancer progression, therapy response, and metastatic dissemination in solid tumours. In particular we work on the role of post-translational modification of the ECM, including Lysyl Oxidase (LOX) and Lysyl Oxidase Like (LOXL) family members. Our work looks at the importance of these changes in regulating both the biochemical and biomechanical properties of the ECM during fibrosis, cancer progression and metastasis. These ECM changes lead to significant alterations in cellular response to drugs, and we work to understand how we can use dual therapy approaches to improve drug efficacy. Our research includes multidisciplinary, international collaborative projects working with biologists, physicists, engineers and clinicians to study disease progression at a systems biology level.